My Account
Amgen
SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are indicative only and not appropriate for trading purposes. Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
$52042
5
2
.
0
4
2
-0.78 (-0.32%)
As on 30 Mar, 2023 | 22:17 IST
Day Range
240.11
242.81
LH
52 Week Range
223.30
296.67
LH
| Open | 242.04 |
| Previous Close | 241.03 |
| Beta | 0.05 |
| High | 242.81 |
| Low | 240.11 |
| TTM EPS See historical trend | 17.69(+3.39% YoY) |
| 52 Week High | 296.67 |
| 52 Week Low | 223.30 |
| TTM PE See historical trend | 13.58(Average PE) |
| Mkt. Cap ($ Billion) | 128.29 |
| Dividend Yield | 3.44 |
Advance Chart
*Delayed by 20 seconds.
MC Technicals
Moving Averages
| Days | |
|---|---|
| 5 | 238.96 |
| 10 | 235.52 |
| 20 | 233.46 |
| 50 | 240.26 |
| 100 | 258.19 |
| 200 | 251.29 |
Returns
Price Performance
| 1 Week | 3.07% | |
| 1 Month | 3.71% | |
| 3 Months | -8.49% | |
| YTD | -8.49% | |
| 1 Year | -0.96% | |
| 3 Years | 15.24% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| J&J | 153.00 | -0.20 | 400.02 | 15.06 | 10.16 | 2.77 | 186.69/150.11 | -0.17 | Bearish |
| Eli Lilly | 337.61 | 0.52 | 320.79 | 41.73 | 8.09 | 1.21 | 384.44/276.83 | 8.48 | Bullish |
| AbbVie | 157.74 | -0.16 | 278.96 | 11.35 | 13.90 | 4.20 | 175.91/134.09 | 2.50 | Very Bullish |
| Merck & Co | 105.59 | 0.64 | 267.71 | 14.12 | 7.48 | 3.20 | 115.49/81.64 | -0.61 | Bearish |
| Pfizer | 40.29 | 0.10 | 226.16 | 6.08 | 6.63 | 3.66 | 56.32/39.23 | -0.69 | Bearish |
Market news
- Bernstein's Venugopal Garre: Nifty might correct till 16000 levels and then recover by the end of this yearMarch 29, 2023 2:20 PM
- Wall Street ends down with tech; investors assess bank commentsMarch 29, 2023 6:07 AM
- S&P 500 ends up slightly; SVB deal lifts bank sharesMarch 28, 2023 6:04 AM
- Transparency and disclosure key to addressing risks to global financial stability, says IMF reportMarch 27, 2023 11:37 AM
About the company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.